Literature DB >> 2744938

Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation).

J Pecori Giraldi1, M Virno, G Covelli, G Grechi, F De Gregorio.   

Abstract

The favourable neurotrophic effects obtained by means of the intramuscular administration of citicoline, one of the intermediate compounds of phospholipids, on the visual field of patients suffering from open-angle glaucoma are referred. The drug was administered at the dose of 1 gm for ten consecutive days. Visual field was examined by means of central computerized perimetry and automated perimetry. All patients had well controlled intraocular pressure through beta-blockers, but presented characteristic glaucomatous perimetric defects. It is suggested that citicoline might be administered as a useful complement to conventional hypotensive therapy, since it acts positively on the glaucomatous optic nerve damage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744938     DOI: 10.1007/bf02028649

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  2 in total

1.  Computerized video screen perimetry.

Authors:  N Accornero; A Berardelli; G Cruccu; M Manfredi
Journal:  Arch Ophthalmol       Date:  1984-01

2.  [Automatic topography of the central visual field (between 20) of glaucoma patients].

Authors:  L Taverniti; N Accornero
Journal:  Bull Mem Soc Fr Ophtalmol       Date:  1983
  2 in total
  18 in total

1.  Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up.

Authors:  Vincenzo Parisi
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

2.  Effect of oral CDP-choline on visual function in young amblyopic patients.

Authors:  Michela Fresina; Anna Dickmann; Annabella Salerni; Fabio De Gregorio; Emilio C Campos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-19       Impact factor: 3.117

3.  Effect of citicoline on visual acuity in amblyopia: preliminary results.

Authors:  E C Campos; C Schiavi; P Benedetti; R Bolzani; V Porciatti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-05       Impact factor: 3.117

4.  Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control.

Authors:  Yolandi van der Merwe; Matthew C Murphy; Jeffrey R Sims; Muneeb A Faiq; Xiao-Ling Yang; Leon C Ho; Ian P Conner; Yu Yu; Christopher K Leung; Gadi Wollstein; Joel S Schuman; Kevin C Chan
Journal:  Neurotherapeutics       Date:  2021-04-13       Impact factor: 7.620

Review 5.  Neuroprotection in Glaucoma: Old and New Promising Treatments.

Authors:  Dario Rusciano; Salvatore Pezzino; Maria Giulia Mutolo; Rossella Giannotti; Aloisa Librando; Nicola Pescosolido
Journal:  Adv Pharmacol Sci       Date:  2017-10-17

Review 6.  Management of amblyopia in pediatric patients: Current insights.

Authors:  Sagnik Sen; Pallavi Singh; Rohit Saxena
Journal:  Eye (Lond)       Date:  2021-07-07       Impact factor: 3.775

7.  A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy.

Authors:  Gloria Roberti; Lucia Tanga; Vincenzo Parisi; Massimo Sampalmieri; Marco Centofanti; Gianluca Manni
Journal:  Indian J Ophthalmol       Date:  2014-05       Impact factor: 1.848

Review 8.  Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma.

Authors:  Pawel Grieb; Anselm Jünemann; Marek Rekas; Robert Rejdak
Journal:  Front Aging Neurosci       Date:  2016-04-08       Impact factor: 5.750

Review 9.  Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives.

Authors:  Gloria Roberti; Lucia Tanga; Manuele Michelessi; Luciano Quaranta; Vincenzo Parisi; Gianluca Manni; Francesco Oddone
Journal:  Int J Mol Sci       Date:  2015-11-30       Impact factor: 5.923

Review 10.  Neuroprotective agents in the management of glaucoma.

Authors:  C Nucci; A Martucci; C Giannini; L A Morrone; G Bagetta; R Mancino
Journal:  Eye (Lond)       Date:  2018-02-23       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.